Table 4.
Results of the dynamic model of meningococcal disease and vaccination in England.
| Discounted cost per QALY gained (£) |
|||||
|---|---|---|---|---|---|
| Discounting of costs | Base casea | 3.5% | 5.0% | 6.0% | |
| Discounting of benefits | 3.5% | 5.0% | 1.5% | ||
| A | 2,3,4 + 12 months | 96,000 | 116,200 | 158,000 | £27,900 |
| B | 2,4,6 + 12 months | 91,800 | 111,700 | 153,100 | £26,800 |
| D | Routine infant 2,3,4 + 12 months of age plus catch-up in 1–4 year olds (0,2,6 schedule) | 97,600 | 117,700 | 161,800 | £30,700 |
| E | Routine infant 2,3,4 + 12 months of age plus catch-up in 1–4 year olds (0,2,6 schedule) and 5–17 year olds (0,2 schedule) | 83,400 | 97,900 | 135,000 | £30,600 |
| F | Adolescent: 0, 2, 6 schedule | 40,200 | 54,000 | 84,500 | £12,600 |
| G | Routine adolescent (0,2,6 schedule) plus catch-up in 13–17 year olds (0,2,6 schedule) | 39,200 | 51,600 | 81,100 | £13,800 |
Results from the base case dynamic model showing the effect of varying the discount rates on the cost per Quality Adjusted Life Year; 60% vaccine effectiveness against carriage, 75% vaccine effectiveness against disease in infants, 80% vaccine effectiveness against disease in catch-up cohorts, £40 per vaccine dose, costs in GBP (£) rounded to nearest £100. Please see Table 2 for further details of the strategies modelled.
a
3.5% for the first 30 years, 3.0% for years 31–75, 2.5% for years 76 to 100.